Free Trial
NASDAQ:QURE

uniQure Q1 2024 Earnings Report

uniQure logo
$10.07 -1.41 (-12.25%)
Closing price 03:59 PM Eastern
Extended Trading
$9.97 -0.10 (-1.03%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

uniQure EPS Results

Actual EPS
-$1.36
Consensus EPS
-$1.31
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

uniQure Revenue Results

Actual Revenue
$8.49 million
Expected Revenue
$2.58 million
Beat/Miss
Beat by +$5.91 million
YoY Revenue Growth
N/A

uniQure Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, May 7, 2024
Conference Call Time
4:00PM ET

uniQure Earnings Headlines

uniQure to Announce First Quarter 2025 Financial Results
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
See More uniQure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like uniQure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on uniQure and other key companies, straight to your email.

About uniQure

uniQure (NASDAQ:QURE) N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

View uniQure Profile

More Earnings Resources from MarketBeat